Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE ‘fast-tracking’ underlines threat from BMS/Pfizer’s Eliquis to Pradaxa and Xarelto

This article was originally published in Scrip

Executive Summary

The positive reimbursement decision from NICE on 23 January means that Bristol-Myers Squibb/Pfizer's Eliquis (apixaban) means will likely start competing with Boehringer Ingelheim's Pradaxa (dabigatran etexilate) and Bayer's Xarelto (rivaroxaban) in stroke prevention as early as next month, February 2013. Datamonitor analyst Victoria Hudson, says Eliquis will compete well against its rival novel anticoagulants even in a market where uptake of warfarin-replacements has been slower than expected.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts